Here’s a rewritten version of the article,aiming for 100% uniqueness while preserving all verifiable information:
Gilead Sciences‘ Yeytuo Hailed as Major Breakthrough in HIV Prevention
Yeytuo,a groundbreaking drug developed by the American biotechnology and pharmaceutical firm Gilead Sciences,is being recognized as a notable advancement in the global effort to combat the HIV virus. Agency representatives, in a statement released on friday and reported by AP News, described the treatment as “highly effective” and “of considerable importance to public health.”
Upon official endorsement by the European Commission, this innovative treatment will become accessible across all 27 EU Member states, in addition to Iceland, Norway, and Liechtenstein.
Administered twice Annually with Near-Perfect Efficacy
lenacapavir has already received approval from the U.S. Food and Drug Management (FDA) in June. More recently, the World Health Organization has recommended its inclusion as an additional option for individuals at risk of HIV infection.Distinguishing itself from existing preventive measures,such as daily oral medications or injections administered every two months (like Cabotegravir),Lenacapavir provides protection for a full six months. This extended duration of efficacy could appeal to individuals who may face challenges with frequent clinic visits or who wish to avoid the stigma associated with more regular treatment schedules.
Research conducted last year demonstrated that Lenacapavir is nearly 100% effective in preventing HIV transmission for both women and men. Winnie Byanyima, Executive Director of UNAIDS, the Joint United Nations Program on HIV/AIDS, expressed optimism, stating, “This medicine has the potential to alter the course of the HIV epidemic, provided it is indeed accessible to everyone who requires it.”
Global Access crucial for Virus Containment
However, concerns have been raised regarding equitable access to Lenacapavir worldwide. While Gilead Sciences has committed to permitting the production of affordable generic versions in 120 low-income countries, predominantly in Africa and Southeast Asia, a significant portion of Latin America has been excluded from this initiative. This decision has fueled anxieties that the world might forfeit a critical chance to curb the virus’s global spread.
The HIV virus was first identified in the early 1980s, following the emergence of unusual immunodeficiency symptoms in several patients.Since its identification, HIV has been responsible for over 40 million deaths globally, with a comparable number of individuals currently living with the virus.
According to UNAIDS data, approximately 630,000 deaths attributed to HIV were reported in 2024.
Gilead Sciences, as the originator of Lenacapavir, is granting non-exclusive, royalty-free licenses to generic manufacturers to facilitate broader access to the drug in specific regions.